跳至主要内容
临床试验/EUCTR2018-001829-11-GB
EUCTR2018-001829-11-GB进行中(未招募)1 期

The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness Study. Carboprost vs Oxytocin as the First Line Treatment of Primary Postpartum Haemorrhage; A phase IV, double-blind, double-dummy, randomised controlled trial. - COPE

niversity of Liverpool0 个研究点目标入组 3,948 人开始时间: 2019年11月12日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
3,948

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • = 16 years of age
  • Requirement for medical treatment for primary PPH
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 198
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 3750
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Known to have opted out of participation antenatally
  • Known oxytocin or carboprost hypersensitivity
  • Known active cardiac or pulmonary disease
  • Known to have previously been treated as part of COPE
  • Has already received carboprost prophylactically for postpartum haemorrhage
  • Has already received uterotonic drug treatment for postpartum haemorrhage (this does not include PPH prophylaxis)

研究者

发起方
niversity of Liverpool

相似试验